醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床研究

发布时间：2018-03-21 20:58

本文选题：醒脑静注射液　切入点：阿托伐他汀钙胶囊　出处：《中国临床药理学杂志》2017年09期 　论文类型：期刊论文

【摘要】：目的观察醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床疗效及安全性。方法 68例急性脑出血患者随机分为对照组34例与试验组34例,2组均给予常规治疗以及对症治疗。对照组给予阿托伐他汀钙胶囊20 mg,每日1次,口服,试验组在对照组的基础上给予醒脑静注射液20 m L,每日2次,静脉滴注。2组均治疗21 d。比较2组患者的临床疗效、治疗前后血清C反应蛋白(CRP)、白细胞介素-1β(IL~(-1)β)、肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)、丙二醛(MDA)和超氧化物歧化酶(SOD)水平及药物不良反应发生情况。结果治疗后,对照组临床总有效率为76.47%(26/34例),试验组为94.12%(32/34例,P0.05)。治疗后,试验组和对照组血清CRP分别为(3.72±0.86),(5.18±0.51)mg·L~(-1),IL~(-1)β分别为(4.02±0.41),(5.48±0.58)ng·L~(-1),TNF-α分别为(19.47±2.13),(29.59±3.04)μg·L~(-1),NO分别为(3.03±0.34),(4.11±0.42)ng·L~(-1),MDA分别为(6.04±0.61),(7.17±0.76)μmol·m L~(-1),SOD分别为(162.01±16.34),(142.63±14.64)U·m L~(-1)(P0.05)。试验组药物不良反应有头痛、恶心、皮疹,药物不良反应发生率为8.82%(3/34例),对照组药物不良反应有头痛、视物模糊、恶心、失眠,药物不良反应发生率为14.70%(5/34例,P0.05)。结论醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床疗效显著,安全性高。
[Abstract]:Objective to observe the clinical efficacy and safety of Xingnaojing injection combined with Atto vastatin calcium capsule in the treatment of acute cerebral hemorrhage. Methods Sixty-eight patients with acute cerebral hemorrhage were randomly divided into control group (n = 34) and experimental group (n = 34). The control group was given 20 mg Atto vastatin calcium capsule once a day. After oral administration, the experimental group was given Xingnaojing injection 20ml twice a day for 21 days. The clinical efficacy of the two groups was compared. Before and after treatment, the levels of serum C-reactive protein (CRPN), interleukin-1 尾 (ILA) 尾, tumor necrosis factor- 伪 (TNF- 伪), nitric oxide (no), malondialdehyde (MDA) and superoxide dismutase (SOD), and the occurrence of adverse drug reactions were observed. The total effective rate of the control group was 76.47 / 26 / 34, and that of the test group was 94.12 / 32 / 34 渭 g / L P 0.05. After treatment, the serum CRP of the experimental group and the control group was 3.72 卤0.861.The CRP of the test group and the control group were respectively 4.02 卤0.411 卤0.61 mol / L and 7.17 卤0.76) mol / L ~ (-1), respectively (19.47 卤2.13 / 34 卤3.04) 渭 g / L ~ (-1) no and 7.17 卤0.76) m / L ~ (-1) mol / L ~ (-1) mol / L ~ (-1) mol / L ~ (-1) no, respectively, respectively, respectively, the adverse reactions of headache and nausea in the experimental group were (19.47 卤2.13) 渭 g / L ~ (-1) ~ (-1) 渭 g / L ~ (-1), respectively (7.17 卤0.76) m ~ (-1) mol / L ~ (-1), respectively. The incidence of adverse drug reactions in the control group was headache, blurred vision, nausea and insomnia. The incidence of adverse drug reactions was 14.70 / 5 / 34 patients with P0.050.Conclusion Xingnaojing injection combined with Atto vastatin calcium capsule is effective and safe in the treatment of acute intracerebral hemorrhage.
【作者单位】：洛阳市中心医院神经内科;
【基金】：河南省科技厅科技攻关基金资助项目(112102310173)
【分类号】：R743.34

【相似文献】